Oss, Netherlands — September 2, 2025 — Leads & Copy — Citryll, a biotech company, has dosed the first patient in its Phase IIa clinical trial “Citydream.” The trial will evaluate CIT-013, a monoclonal antibody, in patients with moderately active rheumatoid arthritis (RA).
Citryll has established an RA Clinical Advisory Board to provide guidance throughout the clinical development of CIT-013 in RA and other autoimmune diseases. The Phase IIa study is randomized, double-blind, placebo-controlled, and multi-center, and will enroll 88 patients for a six-week treatment period.
Maarten Kraan, Chief Medical Officer of Citryll, said the trial represents an important step in validating the potential of CIT-013 in rheumatoid arthritis. Rogier Thurlings, MD, PhD, Lead Investigator of Citydream, said CIT-013 represents a novel and potentially disease-modifying approach to RA and other immune mediated conditions.
CIT-013 targets Neutrophil Extracellular Traps (NETs), a key driver of inflammation in RA and other immune-mediated diseases. It enhances the clearance of existing NETs and inhibits the formation of new NETs.
Contacts: Sjoerd van Gorp, COO, Email: info@citryll.com; Citryll Media Contacts: Amber Fennell, Stephanie Cuthbert, Lucy Featherstone, Email: citryll@icrinc.com
Source: Citryll
